Silo Pharma, Inc. announced a service agreement with Resyca BV to conduct a drug-device study on its microchip-based nasal spray system for SPC-15, an intranasal treatment for PTSD. This study aims to ...
Study to test effectiveness of Instructional System Designs (ISD) model for Intranasal SPC-15 ENGLEWOOD CLIFFS, NJ, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Silo Pharma (SILO), Inc. (“the Company”), a ...
SARASOTA, FL, May 14, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery ...
(RTTNews) - Silo Pharma, Inc. (SILO), Monday announced positive results from a pre-clinical study of SPC-15 showing potential for the treatment of major depressive disorder, and other severe ...
Silo Pharma, Inc. has announced an agreement with Frontage Laboratories to conduct a 7-day safety and toxicology study on its lead drug, SPC-15, an intranasal treatment for PTSD. This study aims to ...
A new economic impact study says South Plains College produces significant returns for the area's economy, students, businesses and taxpayers. The study reached three major conclusions. South Plains ...
No new PTSD drug approvals in the U.S. in nearly 25 years; large potential addressable market for SPC-15 worldwide SARASOTA, FL, July 07, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback